Standard BioTools (LAB) Stock Price
Standard BioTools Price
Standard BioTools (LAB) Stock | ISIN US34385P1084 | WKN A0RADJ. The current Standard BioTools stock price is 0.8 USD (2026). Revenue is 80.52 M USD. Net income is -60.2 M USD. The P/E ratio is -4.71. Market capitalization is 308.73 M USD. Standard BioTools operates in the Health sector.
Revenue has compounded at 17.8% per year over the past 19 years to 174.43 M USD. Standard BioTools's net margin stands at -106%, down from -38.4% several years earlier.
Standard BioTools stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Standard BioTools over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Standard BioTools stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Standard BioTools's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Standard BioTools Price |
|---|
Standard BioTools Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Standard BioTools Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|
| 130 | 97 | 106 | 174 | 81 | 80 | 84 | 85 |
| -5.8 | -25.38 | 9.28 | 64.15 | -53.45 | -1.23 | 5 | 1.19 |
| 53.08 | 38.14 | 47.17 | 48.28 | 103.7 | 105 | 100 | 98.82 |
| 69 | 37 | 50 | 84 | 84 | 84 | 84 | 84 |
| -59 | -190 | -74 | -184 | -100 | -60 | -54 | - |
| 11.32 | 222.03 | -61.05 | 148.65 | -45.65 | -40 | -10 | – |
| 75.8 | 78.3 | 79.16 | 353.25 | 353.25 | 353.25 | 353.25 | 353.25 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Standard BioTools generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Standard BioTools retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Standard BioTools's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Standard BioTools has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Standard BioTools's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Standard BioTools stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Standard BioTools Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Standard BioTools business model & stock analysis
Standard BioTools SWOT Analysis
Strengths
1. Innovative Products: Fluidigm Corp is known for its advanced and cutting-edge technologies that enable the analysis of individual cells, empowering researchers with high-throughput and single-cell analysis capabilities.
2. Strong Intellectual Property (IP) Portfolio: The company possesses a significant number of patents and intellectual property rights, providing a competitive advantage and protection against potential imitators in the market.
3. Market Leadership: Fluidigm Corp holds a prominent position in the life sciences industry, with a strong brand reputation and a wide customer base that includes leading academic institutions, biotechnology companies, and pharmaceutical organizations.
Weaknesses
1. Reliance on Research Funding: The company heavily depends on government grants and research funding, which can be unpredictable and subject to budget constraints, potentially impacting their financial stability.
2. High Research and Development (R&D) Costs: Developing and commercializing highly innovative products require substantial investments in R&D, which puts pressure on the company's financial resources and profitability.
3. Market Volatility: The life sciences industry is highly competitive and subject to rapid technological advancements. Fluidigm Corp needs to continuously adapt to changing market dynamics and customer preferences to maintain its competitive edge.
Opportunities
1. Growing Demand for Single-Cell Analysis: With the increasing interest in personalized medicine and advancements in genomics research, there is a significant opportunity for Fluidigm Corp to capture market share by providing solutions for high-throughput single-cell analysis.
2. Expansion into New Geographical Markets: The company can explore untapped international markets, especially in regions with a rising focus on life sciences research, such as Asia-Pacific. Expanding the customer base beyond traditional markets would help drive revenue growth.
3. Collaboration and Partnerships: Fluidigm Corp can seek strategic collaborations and partnerships with key players in the industry to leverage complementary expertise, access new technologies, and tap into untapped market segments.
Threats
1. Competitive Landscape: The life sciences industry is highly competitive, with several established players and emerging startups continuously introducing new products and technologies. Fluidigm Corp needs to stay vigilant to avoid losing market share.
2. Regulatory and Compliance Challenges: Changes in regulatory requirements and compliance standards can pose challenges for Fluidigm Corp, requiring additional investments and potentially delaying product launches.
3. Economic Uncertainty: Economic downturns or fluctuations can impact research budgets, potentially leading to reduced spending on innovative technologies offered by Fluidigm Corp.
Standard BioTools Segments
Standard BioTools Revenue by Segment (1/5)
3 Years
Max
Details
Standard BioTools Revenue by Segment (2/5)
3 Years
Max
Details
Standard BioTools Revenue by Segment (3/5)
3 Years
5 Years
10 Years
25 Years
Max
Details
Standard BioTools Revenue by Segment (4/5)
3 Years
5 Years
10 Years
25 Years
Max
Details
Standard BioTools Revenue by Segment (5/5)
3 Years
Max
Details
Standard BioTools Revenue by Region
3 Years
5 Years
Max
Details
Standard BioTools Eulerpool Fair Value
Standard BioTools historical P/E ratio, EBIT multiple, and P/S ratio
Standard BioTools annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Standard BioTools shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Standard BioTools Earnings Estimates
Standard BioTools Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/12/2026 | -0.06USD | 17.99 MUSD | 2026 Q1 |
| 5/4/2026 | -0.06USD | 17.99 MUSD | 2026 Q1 |
| 2/24/2026 | -0.07USD | 18.69 MUSD | 2025 Q4 |
| 2/18/2026 | -0.07USD | 18.69 MUSD | 2025 Q4 |
| 8/11/2025 | -0.08USD | 40.22 MUSD | 2025 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Standard BioTools stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Standard BioTools shareholder structure
| % | Name |
|---|---|
20.03767% | |
15.2511% | |
5.66688% | |
4.402% | |
2.61851% | |
1.93492% | |
1.63853% | |
1.45885% | |
1.4555% | |
1.40204% |
Standard BioTools Executives and Management Board
Dr. Michael Egholm
(62)President, Chief Executive Officer, Director · since 2022
Mr. Sean Mackay
(42)Chief Business Officer
Mr. Hanjoon Kim
(54)Chief Financial Officer
Mr. Thomas Carey
(63)Independent Chairman of the Board
Dr. Franklin Witney
(71)Independent Director
Standard BioTools Supply Chain
Frequently asked questions about Standard BioTools
The business model of Fluidigm Corp focuses on providing innovative technologies for large-scale biological research. The company develops and sells microfluidic systems, instruments, consumables, and software solutions that enable scientists to analyze biological systems at the cellular level. Fluidigm Corp's platforms are designed to enhance workflows and deliver high-quality data for a wide range of applications, including genomics, proteomics, and single-cell analysis. By offering comprehensive and advanced solutions, Fluidigm Corp aims to empower researchers in their quest for new discoveries and deeper understanding of biological processes.
Standard BioTools stock
Standard BioTools Peer Group
Standard BioTools Ticker
Standard BioTools FIGI
All fundamentals and in-depth analysis of Standard BioTools
Our stock analysis for Standard BioTools Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Standard BioTools Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.